#USA #oncology #IDEAYA Biosciences #South San Francisco #targeted therapies

IDEAYA Biosciences Engages Investors

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a cutting-edge precision medicine oncology firm, has recently confirmed its participation in two pivotal investor relations events scheduled for December 2024. These gatherings are important opportunities for the company to showcase its commitment to developing targeted therapeutics tailored for distinct patient populations identified through molecular diagnostics.

Event Highlights

The first event is the Citi's 2024 Global Healthcare Conference, taking place on December 3rd, 2024, at 8:00 AM ET. During this conference, IDEAYA's President and CEO, Yujiro S. Hata, will engage in a fireside chat facilitated by Yigal D. Nochomovitz, Ph.D., a prominent figure in Mid-Cap Biotech analysis.

The following day, on December 4th, 2024, at 12:00 PM ET, IDEAYA will participate in the 7th Annual Evercore HealthCONx Conference. Here again, Hata will partake in a fireside chat, this time led by Jonathan Miller, the Managing Director of Biotech and Pharma Equity Research. Both sessions will enable IDEAYA to outline its strategic vision and highlight significant advancements in its research.

For those interested, a live audio webcast of both events will be accessible through IDEAYA's official website under the 'Investors/Events' section (https://ir.ideayabio.com/events). Additionally, a replay of the presentations will be available for 30 days after the events, ensuring wider accessibility to interested stakeholders.

About IDEAYA Biosciences

IDEAYA specializes in precision medicine focused on oncology. The company's mission is to discover and develop targeted therapeutics that leverage molecular diagnostics for optimized patient selection. By identifying and validating translational biomarkers, IDEAYA enhances its capability to choose patient populations most likely to benefit from innovative therapies. One of the key areas of focus is synthetic lethality, an emerging precision medicine target that IDEAYA is well poised to explore further.

The combination of these investor events underscores IDEAYA's proactive approach in engaging with the financial community while also promoting its pivotal role in advancing oncology therapies. As the healthcare landscape continues to evolve, such efforts are integral for stakeholders looking to understand the future trajectory of targeted therapeutics development.

Moving Forward

While IDEAYA Biosciences is enthusiastic about the upcoming conferences, it also emphasizes that all statements regarding its participation are forward-looking. The company has not committed to updating these statements, reflecting the inherently unpredictable nature of the biotech and healthcare sectors. For ongoing coverage of the company's developments, stakeholders are encouraged to review IDEAYA's filings with the U.S. Securities and Exchange Commission, including key documents like the Annual Report on Form 10-K filed on February 20, 2024. This transparency helps investors stay informed about the potential opportunities and risks associated with IDEAYA’s business trajectory.

In conclusion, IDEAYA Biosciences is on an exciting path, promoting groundbreaking therapeutics while maintaining open channels of communication with both investors and the public. The upcoming events in December are sure to attract significant attention as IDEAYA continues to shape the future of precision oncology.